FAQ: Gilead’s LENACAPAVIR (LEN-LA) license and implications for access
The following FAQ unpacks the implications of the US pharmaceutical corporation Gilead Sciences’s licence for lenacapavir.
It is drawn from expert and sector contributions, and a first version was presented to the SA National AIDS Council (SANAC) in November 2024.
